Skip to main page content

• HOME
• Current
• Archive
• Feedback
• Subscribe
• Help

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by CREED, F. Search for Related Content PubMed PubMed Citation Articles by CREED, F.

Outcome in severe irritable bowel syndrome with and without accompanying depressive, panic and neurasthenic disorders

JOY RATCLIFFE, MRCPsych

School of Psychiatry and Behavioural Science, University of Manchester

LAKSHMI FERNANDES, MRCPsych

Department of Psychiatry, University of Sheffield

STEPHEN PALMER, MSc

Centre for Health Economics, University of York

CHRISTINE RIGBY, MSc, BARBARA TOMENSON, MSc and ELSPETH GUTHRIE, MD, MRCPsych

School of Psychiatry and Behavioural Science, University of Manchester

NICHOLAS READ, MD, FRCP

Institute of General Practice, Northern General Hospital, Sheffield

DAVID G. THOMPSON, FRCP

Section of Gastrointestinal Science, Hope Hospital, University of Manchester, Manchester, UK

North of England IBS Research Group

Correspondence: Professor Francis Creed, School of Psychiatry and Behavioural Science, Rawnsley Building, Oxford Road, Manchester M13 9WL, UK. Tel: +44 (0)161 276 5331/5397; fax: +44 (0)161 273 2135; e-mail: francis.creed{at}man.ac.uk

Declaration of interest F.H.C. has consultancy links with Eli Lilly and Lundbeck; S.P. has consultancy links with AstraZeneca and Eli Lilly.

Background Irritable bowel syndrome often leads to impaired functioning.

Aims To assess the contribution of psychiatric disorders to impaired outcome in severe irritable bowel syndrome.

Method Patients with severe irritable bowel syndrome entering a psychological treatment trial (n=257) were interviewed using the Schedules for Clinical Assessment in Neuropsychiatry. Outcomes were number of days of restricted activity, role limitation (physical) score of the Short Form Health Survey and costs.

Results At baseline, depressive disorder (29% of patients), panic (12%) and neurasthenia (35%) were associated with impairment; number of psychiatric disorders was associated in a dose-response fashion (P=0.005). At follow-up, depressive disorder and neurasthenia were associated with role limitation score. Improved depression was associated with improved role functioning.

Conclusions Depressive, panic and neurasthenic disorders contribute to poor outcomes in severe irritable bowel syndrome, and appropriate treatment should be available to these patients.

This article has been cited by other articles:

				P. P. Roy-Byrne, K. W. Davidson, R. C. Kessler, G. J.G. Asmundson, R. D. Goodwin, L. Kubzansky, R. B. Lydiard, M. J. Massie, W. Katon, S. K. Laden, et al. Anxiety Disorders and Comorbid Medical Illness Focus, September 1, 2008; 6(4): 467 - 485. [Abstract] [Full Text] [PDF]

				M. M. Heitkemper and M. E. Jarrett Update on Irritable Bowel Syndrome and Gender Differences Nutr Clin Pract, June 1, 2008; 23(3): 275 - 283. [Abstract] [Full Text] [PDF]

				R Spiller, Q Aziz, F Creed, A Emmanuel, L Houghton, P Hungin, R Jones, D Kumar, G Rubin, N Trudgill, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management Gut, December 1, 2007; 56(12): 1770 - 1798. [Abstract] [Full Text] [PDF]

				M. P. Jones, M. D. Crowell, K. W. Olden, and F. Creed Functional Gastrointestinal Disorders: An Update for the Psychiatrist Psychosomatics, April 1, 2007; 48(2): 93 - 102. [Abstract] [Full Text] [PDF]

				F Creed How do SSRIs help patients with irritable bowel syndrome? Gut, August 1, 2006; 55(8): 1065 - 1067. [Full Text] [PDF]